How Durata Plans To Market Its Expensive New Antibiotic

June 5, 2014 2:15 PM

73 0

How Durata Plans To Market Its Expensive New Antibiotic

FDA’s approval on May 23 of Durata Therapeutics Durata Therapeutics Inc.’s antibiotic Dalvance (dalbavancin) underscores the potential and also the challenges life science companies face in grappling with new payment and delivery reform models, some driven by the Affordable Care Act (ACA), but also independent of it. The drug is indicated for adults with complex skin infections (acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)}. It’s one of a series of new antibiotics coming to market after years in which pharma neglected the space.

Durata execs have been forthcoming about how healthcare reforms are shaping their strategy for introducing an expensive new antibiotic into the cost conscious, radically-changing hospital sector. But it’s worth a closer look because its executives have put forth the kind of cost benefit argument th...

Read more

To category page